Viridian Therapeutics, Inc.

VRDN · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.2%

Institutions126.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$70.85M	$302000	$314000	$1.77M	$2.96M	$1.05M	$4.46M	$8.39M	$4.00M	$3.34M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	–	–	–	–	–	–	–	–	$2.55M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$363.39M	-$299.04M	-$254.45M	-$134.30M	-$79.73M	-$110.38M	-$41.98M	-$33.08M	-$26.53M	-$12.51M
Operating income as a percentage of revenue.	-512.9%	-99018.2%	-81035.0%	-7579.2%	-2690.8%	-10512.4%	-941.0%	-394.5%	-662.8%	-374.8%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$342.60M	-$269.95M	-$237.73M	-$129.87M	-$79.41M	-$110.72M	-$41.87M	-$32.70M	-$26.51M	-$12.67M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-446.62	$-412.71	$-5.00	$-4.00	$-6.66	$-31.13	$-1.00	$-1.00	$-1.00	$-17.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-446.62	$-412.71	$-5.00	$-4.00	$-6.66	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$212.38M	$99.59M	$102.83M	$155.58M	$42.30M	$45.90M	$24.85M	$32.61M	$47.44M	$3.34M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$899.42M	$742.40M	$490.42M	$435.09M	$203.71M	–	$30.26M	$66.15M	$52.48M	$4.26M
All of the company's interest-bearing borrowings, short and long term combined.	$34.24M	$20.58M	–	–	–	$0	$3.98M	$2.29M	$0	–
Everything the company owes — debt, unpaid bills, and other obligations.	$177.25M	$70.76M	$48.40M	$40.03M	$15.99M	–	$14.51M	$14.80M	$13.97M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$722.17M	$671.64M	$442.02M	$395.06M	$187.72M	–	$15.75M	$51.34M	$38.51M	-$326000

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$276.39M	-$232.32M	-$184.17M	-$93.84M	-$54.58M	-$29.78M	-$36.06M	-$26.84M	-$28.17M	-$7.23M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$495000	$511000	$898000	$797000	$338000	$42000	$84000	$445000	$246000	$3000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$276.89M	-$232.83M	-$185.07M	-$94.64M	-$54.92M	-$29.82M	-$36.14M	-$27.29M	-$28.41M	-$7.23M

	You	Peer avg
P/E	–	13.7
Revenue Growth	+278.7%	-10.9%
ROE	-65.7%	-163.2%

Viridian Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison